SCHEMBL16645108

SCHEMBL16645108

CC(C)(C)OC(=O)N1CCc2cc(NS(=O)(=O)c3ccccn3)ccc2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.53
NR1H2 P55055 1/20 0.47
NAMPT P43490 4/20 0.47
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
JAK2 O60674 2/20 0.42
JAK3 P52333 2/20 0.42
PTK2 Q05397 2/20 0.42
GPR119 Q8TDV5 1/20 0.42
GRM5 P41594 1/20 0.42
SCN9A Q15858 1/20 0.42
KCNA1 Q09470 2/20 0.41
KCNAB1 Q14722 2/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17969243 0.85 KCNA1 (0.46) NAMPTNPC1RAB9AKCNA1KCNAB1
SCHEMBL4789781 0.83 ESR2 (0.66) ESR2NR1H2NAMPTMAPTMAPK1
SCHEMBL3154277 0.82 NAMPT (0.54) ESR2NR1H2NAMPTMAPTJAK2
SCHEMBL3155935 0.82 ESR2 (0.54) ESR2NR1H2NAMPTNPC1RAB9A
SCHEMBL3153735 0.81 ESR2 (0.53) ESR2NR1H2NAMPTMAPTKCNA1
SCHEMBL3142771 0.81 ESR2 (0.53) ESR2NR1H2NAMPTMAPTMAPK1
SCHEMBL1187213 0.80 ESR2 (0.54) ESR2NR1H2NAMPTMAPTMAPK1
SCHEMBL5778881 0.79 KCNA1 (0.57) ESR2NR1H2NPC1RAB9AKCNA1
SCHEMBL5600152 0.78 NR1H2 (0.65) ESR2NR1H2NAMPTMAPTMAPK1
SCHEMBL16645111 0.78 ESR2 (0.60) ESR2NR1H2NAMPTMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
WO-2015054060-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS NAMPT, NAPRT, NNMT ESR2 4495/4885NR1H2 2307/4885NAMPT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.